First Manhattan’s Sagimet Biosciences SGMT Stock Holding History

First Manhattan’s Portfolio SGMT Stock Details SGMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-537	Closed	-$2.91K	–	1193
2024 Q1	$2.91K	Buy	+537	New	+$3.86K	﹤0.01%	1252

Other funds holding SGMT

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

BOCH

Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

First Manhattan's SGMT Position: Q2 2024 in Review

First Manhattan sold out of Sagimet Biosciences (SGMT) in Q2 2024, closing a stake of 537 shares — an estimated $2.91K sold.

First Manhattan first reported a position in SGMT in Q1 2024 and held it in 1 quarter. The position peaked at $2.91K in Q1 2024. 82 funds tracked by Wall St. Rank hold SGMT as of Q2 2024.

First Manhattan reported no remaining Sagimet Biosciences position as of Q2 2024 after selling out during the quarter.
First Manhattan sold 537 Sagimet Biosciences shares in Q2 2024, an estimated $2.91K.
First Manhattan first reported a position in Sagimet Biosciences in Q1 2024 and held it in 1 quarter.
First Manhattan's Sagimet Biosciences position peaked at $2.91K in Q1 2024.
82 funds tracked by Wall St. Rank held Sagimet Biosciences as of Q2 2024.

Based on First Manhattan's 13F filing for Q2 2024, filed 14 Aug 2024.